Immunology – classification of eye lens antigens Lens antigens of the eye, which are normally hidden from immune recognition under physiological conditions, are best described as:

Difficulty: Easy

Correct Answer: Sequestrated antigens

Explanation:


Introduction / Context:
Certain body sites (eye, brain, testis) are immunologically privileged, meaning their antigens are isolated from the immune system under normal conditions. Eye lens proteins provide a classical example.


Given Data / Assumptions:

  • Lens proteins are not normally exposed to immune surveillance.
  • Exposure may occur after trauma or surgery.
  • Immune response against these antigens may lead to autoimmunity.


Concept / Approach:
Sequestrated antigens are hidden (sequestered) in anatomical locations without lymphatic drainage or exposure. When released, they can be recognized as “foreign” by the immune system despite being self-antigens, provoking autoimmunity. This is distinct from cross-reacting antigens (shared epitopes with microbes) and neoantigens (new epitopes created by mutation or chemical alteration).


Step-by-Step Solution:
Step 1: Define sequestrated antigens as self-antigens normally hidden from immune system.Step 2: Identify lens proteins as such an example.Step 3: Select “Sequestrated antigens” as correct.


Verification / Alternative check:
Clinical examples include sympathetic ophthalmia, an autoimmune condition triggered by lens antigen exposure following ocular injury.


Why Other Options Are Wrong:

  • Cross-reacting antigens: involve mimicry with microbial epitopes, not sequestration.
  • Neoantigens: result from mutations or modifications, not anatomical sequestration.
  • None: incorrect because sequestration is a well-established category.
  • Self-antigens with molecular mimicry: different mechanism, not sequestration.


Common Pitfalls:
Confusing sequestrated with cross-reactive antigens; only sequestrated antigens are physically hidden from immune surveillance.


Final Answer:
Sequestrated antigens.

Discussion & Comments

No comments yet. Be the first to comment!
Join Discussion